Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
- 28 February 2011
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 11 (2) , 91-101
- https://doi.org/10.1016/s1473-3099(10)70296-6
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre studyBMJ, 2010
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus InfectionNew England Journal of Medicine, 2010
- Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects modelBMC Medical Research Methodology, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Reproducibility of Serologic Assays for Influenza Virus A (H5N1)Emerging Infectious Diseases, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972